anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A compound includes a carrier molecule wherein the carrier molecule is linked to a further molecule, wherein the further molecule is at least one cyclic peptide in which the cyclic peptide portion thereof contains at least one sequence encoding a cell receptor recognizing peptide (RRP) and with the proviso that the compound is not a naturally occurring receptor agonist or antagonist. Preferably, the RRP is a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is up-regulated on HSC during disease. The RFP may be chosen from among a PDGF receptor, a collagen type VI receptor, cytokine receptor(s) such as TGBβ, INFα and interleukinβ. The cyclic portion of the peptide can contain at least one amino acid sequence RGD or KPT. The compounds can be used as an active targeting ingredient for manufacturing a pharmaceutical composition for therapy, prophylaxis or diagnosis of a disease chosen from fibrotic disease, sclerotic disease, and chronic or acute inflammatory processes including glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, rheumatoid arthritis, Crohns disease, colitis ulcerosa, glomerulonephritis and sepsis, and particularly for targeting HSC. Pharmaceutical compositions contain the above-compound(s).
Renal fibrosis is a common outcome of various renal injuries, leading to structural destruction and functional decline of the kidney, and is also a critical prognostic indicator and determinant in renal diseases therapy. Hypoxia is induced in different stress and injuries in kidney, and the hypoxia inducible factors (HIFs) are activated in the context of hypoxia in response and regulation the hypoxia in time. Under stress and hypoxia conditions, HIF-1α increases rapidly and regulates intracellular energy metabolism, cell proliferation, apoptosis, and inflammation. Through reprogramming cellular metabolism, HIF-1α can directly or indirectly induce abnormal accumulation of metabolites, changes in cellular epigenetic modifications, and activation of fibrotic signals. HIF-1α protein expression and activity are regulated by various posttranslational modifications. The drugs targeting HIF-1α can regulate the downstream cascade signals by inhibiting HIF-1α activity or promoting its degradation. As the renal fibrosis is affected by renal diseases, different diseases may trigger different mechanisms which will affect the therapy effect. Therefore, comprehensive analysis of the role and contribution of HIF-1α in occurrence and progression of renal fibrosis, and determination the appropriate intervention time of HIF-1α in the process of renal fibrosis are important ideas to explore effective treatment strategies. This study reviews the regulation of HIF-1α and its mediated complex cascade reactions in renal fibrosis, and lists some drugs targeting HIF-1α that used in preclinical studies, to provide new insight for the study of the renal fibrosis mechanism.
Participants will undergo a series of Screening visits prior to treatment and 7- to 14-day follow-up. Healthy volunteers will be enrolled in up to 4 cohorts and will receive RG7625 as oral capsules once or twice daily for 8 days. The first cohort is planned to receive 100 milligrams (mg) on Day 1, followed by 100 mg twice daily on Days 3 to 9. Subsequent dose and frequency decisions will be based upon observations in previous cohort(s). Each cohort will receive intradermal administration of 4 antigens (tetanus toxoid, tuberculin PPD, Candida albicans, and Trichophyton species) and a negative control at Screening and on Day 7 of treatment to assess for DTH.
Observational study in patients undergoing scheduled colonoscopy in endoscopy rooms of the Galdakao-Usansolo Hospital. The investigators objectified the level of sedation that was performed in these procedures using Bispectral Index Monitoring, as well as the total dose of medication required and the level of satisfaction obtained after completing the sedation. The incidence of hemodynamic and respiratory complications observed was included, as well as the treatment needed to solve them.

A total of 196 patients were needed to obtain statistically significant results. Qualitative variables are expressed in the form of freguencies and percentages and continuous variables in the form of means and stnadard deviations. Comparisions of percentages were made by the Chi square test and the difference of means in the continuous variables by the t test.Stadistical significance will be assumed when p\<0.05. All estadistical analyzes were carried out using SAS V9.4 (SAS Institute, Inc., Carey, NC).
Participants will wear Dexcom G6 CGM and will manage their glucose as usual. Participants will be asked to wear a smart watch overnight to collect sleep metrics, weigh themselves weekly in the morning before eating, and answer a one-item sleep quality scale survey weekly.
An exercise challenge will then be performed according to international guidelines. The exercise will consist of 8 minutes of cycling on a cycle ergometer while breathing medical grade dry air from a reservoir (Douglas bag) via a two-way non-rebreathing valve. The workload will be increased progressively over the first 2 minutes, and will then be maintained for 6 minutes at a target workload (in Watts) of \[53.76 \* measured forced expiratory volume in 1 sec (FEV1)-11.07\].
Background: Recent reports have evidenced an increased mortality rate in hypertensive patients with electrocardiographic left ventricular hypertrophy (ECG-LVH) achieving systolic blood pressure (SBP) <130 mmHg. However, to the best of our knowledge, the actual effects of blood pressure reduction to the ≤130/80 mmHg target on the incidence of cardiovascular (CV) events have never been determined in hypertensive patients with a diagnosis of left ventricular hypertrophy based on echocardiographic criteria (Echo-LVH). Methods: To fill this long-standing knowledge gap, we harnessed a population of 9511 hypertensive patients, followed-up for 33.6 [interquartile range 7.9-72.7] months. The population was divided into six groups according to the average SBP achieved during the follow-up (≤130, 130-139, and ≥140 mmHg) and absence/presence of Echo-LVH. The primary endpoint was a composite of fatal or nonfatal myocardial infarction and stroke, sudden cardiac death, heart failure requiring hospitalization, revascularization, and carotid stenting. Secondary endpoints included atrial fibrillation and transient ischemic attack. Results: During the follow-up, achieved SBP and diastolic blood pressure (DBP) were comparable between patients with and without Echo-LVH. Strikingly, the rates of primary and secondary endpoints were significantly higher in patients with Echo-LVH and SBP >130 mmHg, reaching the highest values in the Echo-LVH group with SBP ≥140 mmHg. By separate Cox multivariable regressions, after adjusting for potential confounders, both primary and secondary endpoints were significantly associated with SBP ≥140 mmHg and Echo-LVH. Instead, DBP reduction ≤80 mmHg was associated with a significant increased rate of secondary events. Conclusions: In hypertensive patients with Echo-LVH, achieving an average in-treatment SBP target ≤130 mmHg has a beneficial prognostic impact on incidence of CV events. SIGNIFICANCE STATEMENT: Contrary to recent findings, achieving in-treatment SBP ≤130 mmHg lowers the incidence of CV events in hypertensive patients with Echo-LVH. However, reducing DBP ≤80 mmHg is linked to increased CV complications. Cox multivariable regression models, considering potential confounders, reveal that the rate of hard and soft CV events is significantly associated with Echo-LVH and SBP ≥140 mmHg. Our data indicate that therapeutic strategies for Echo-LVH patients should target SBP ≤130 mmHg while avoiding lowering DBP ≤80 mmHg.
OBJECTIVE: As the ageing process in China further accelerates and the average life expectancy increases, chronic disease prevalence and multimorbidity rates are constantly rising, especially among elderly individuals. However, few previous studies have explored the impacts of chronic diseases and multimorbidity on health-related quality of life (HRQoL). This study aimed to investigate this association among community-dwelling elderly individuals in China.
METHODS: A cross-sectional study was conducted in communities in three cities (Suzhou, Qingdao, and Guangzhou). The basic characteristics, chronic diseases and HRQoL of participants were collected, and HRQoL was measured by the EuroQol 5-Dimensions 3-Level version (EQ-5D-3L). Logistic regression, Tobit regression and generalized linear models were used to assess the impacts of chronic diseases and multimorbidity on HRQoL.
RESULTS: Approximately 83.2 percent of the 1,218 respondents had chronic conditions, with 30 percent having multimorbidity. After controlling for sociodemographic and health behaviour factors, patients with stroke were more likely to report problems in all five dimensions of the EQ-5D and had a lower EQ-5D utility index (UI) (b = -0.342) than patients with other chronic conditions. Patients with chronic pulmonary obstruction had a lower EuroQol Visual Analog Scale (EQ-VAS) (b = -11.169) than patients with other chronic conditions. Furthermore, patients with multimorbidity had worse HRQoL (P < 0.001).
CONCLUSIONS: Both chronic condition probability and multimorbidity rates were high among Chinese community-dwelling elderly individuals. Different disease types had varying degrees of impact on HRQoL, and patients with multimorbidity had worse HRQoL. This study proposes that the government enhance the quality of life of community-dwelling elderly individuals with multimorbidity by establishing long-term care insurance and expanding comprehensive community-based home health care services.
Obstructive sleep apnea (OSA) is a major health problem in the United States and can result in excessive daytime sleepiness and cardiovascular problems. The primary treatment for OSA today is continuous positive airway pressure (CPAP). Many patients however are unable to tolerate sleeping with a CPAP machine. Surgery is one of the main treatment options available today to these CPAP-intolerant patients. However, current methods of sleep surgery are painful, morbid, and/or lack decent effectiveness.

This trial will measure the effectiveness of the Advance System, an implantable medical device to treat OSA. In the trial, patients who meet the study entry criteria receive a baseline sleep study (PSG). The Advance System is then implanted and 6 months after implantation, another PSG is performed. The trial will compare the baseline and the 6 month apnea-hypopnea indices
The active ingredient in gabapentin oral solution is gabapentin, USP, which has the chemical name 1-(aminomethyl)cyclohexaneacetic acid.

The molecular formula of gabapentin, USP is C9H17NO2 and the molecular weight is 171.24. The structural formula of gabapentin, USP is:

Gabapentin, USP is a white to off-white crystalline solid with a pKa1 of 3.7 and a pKa2 of 10.7. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is –1.25.

Gabapentin oral solution contains 250 mg of gabapentin, USP per 5 mL (50 mg per mL) and the following inactive ingredients: acesulfame potassium, carboxymethylcellulose sodium, magnasweet, peppermint flavor, potassium sorbate and strawberry anise flavor. Sodium hydroxide or hydrochloric acid may be added for adjustment of pH.
A method and a composition are provided to promote the differentiation of osteoblast by blocking the function of MEF(Myeloid Elf-1 like Factor) which inhibits the differentiation of the osteoblast. A composition for promoting the differentiation of osteoblast comprises an ingredient blocking the function of ETS transcription factor, which is MEF. The composition is characterized in that the ingredient is an siRNA sequence pair selected from the group consisting of (SEQ ID : NO. 2, SEQ ID : NO. 3), (SEQ ID : NO. 4, SEQ ID : NO. 5), (SEQ ID : NO. 6, SEQ ID : NO. 7), and (SEQ ID : NO. 8, SEQ ID : NO. 9). The method for promoting the differentiation of osteoblast is characterized in that a binding of the MEF to a transcription factor necessary to the osteoblast is blocked.
Participants in this group will be provided with 20 weekly behavioral weight loss (BWL) session (described in more detail in the Intervention section), followed by 6 monthly weight loss maintenance sessions and 3 every-other-month sessions (for a total of 29 visits over 72 weeks). All group meetings will be 90 minutes. Beginning at week 5, BWL content in these sessions will last 60 minutes, with an additional 30 minutes devoted to discussing recipes and food preparation.
Continuous monitoring and closed-loop therapy of soft wound tissues is of particular interest in biomedical research and clinical practices. An important focus is on the development of implantable bioelectronics that can measure time-dependent temperature distribution related to localized inflammation over large areas of wound and offer in situ treatment. Existing approaches such as thermometers/thermocouples provide limited spatial resolution, inapplicable to a wearable/implantable format. Here, we report a conformal, scalable device package that integrates a flexible amorphous silicon-based temperature sensor array and drug-loaded hydrogel for the healing process. This system can enable the spatial temperature mapping at submillimeter resolution and high sensitivity of 0.1 °C, for dynamically localizing the inflammation regions associated with temperature change, automatically followed with heat-triggered drug delivery from hydrogel triggered by wearable infrared light-emitting-diodes. We establish the operational principles experimentally and computationally and evaluate system functionalities with a wide range of targets including live animal models and human subjects. As an example of medical utility, this system can yield closed-loop monitoring/treatments by tracking of temperature distribution over wound areas of live rats, in designs that can be integrated with automated wireless control. These findings create broad utilities of these platforms for clinical diagnosis and advanced therapy for wound healthcare.
PURPOSE:To facilitate the designation of a patient and to easily grasp the state of the patient on the day by displaying names of patients, reserved state and reception state on the day on a display screen as to patient scheduled to be diagnosed on the day. CONSTITUTION:A current date CD, a reserved state SR, names of patients NAM, and remarks NB representing the reception state are displayed on a patient selection pattern 32. Moreover, the patterns are divided into three sub patterns A1-A3 depending on the content of the reserved state SR. The names of patients NAM reserved on the day are displayed on the left sub pattern A1, and the names of patients NAM are in the order of the reservation. Names of patients NAM such as new-patient or patients without reservation are displayed on a middle sub pattern A2. Names of patients NAM not belonging to those for the sub patterns A1, A2 are displayed on the right sub pattern A3. When a patient CAS is selected, a cursor CU is moved to the name of a patient NAM desired to be designated and an execution key is depressed.
MOEG consists of strengthening and balance exercises. Participants were instructed to start the exercises with 5-minute flexibility exercises. The walking component of the original Otago exercises and the stair climbing exercise in the balance exercises were not included in the MOEG. The exercises included 5 strengthening exercises and 11 balance exercises.
Exogenous and endogenous advanced glycation end products (AGEs) contribute to the pathogenesis and progression of renal disease. This is a one-month controlled dietary counseling trial that restricts nutritional AGEs in patients with end-stage renal disease (ESRD) undergoing haemodialysis (n = 22 participants in the intervention and n = 20 participants in the control group). Haematological, biochemical markers, the soluble form of the receptor for AGEs (sRAGE), and carboxymethyl lysine (CML) were measured at baseline and at follow-up. Mononuclear cells were isolated and the protein expression of RAGE and the inflammatory marker COX-2 was measured using Western immunoblotting. The intervention group presented a lower increase in CML compared to the control group (12.39% median change in the intervention vs. 69.34% in the control group, p = 0.013), while RAGE (% mean change -56.54 in the intervention vs. 46.51 in the control group, p < 0.001) and COX-2 (% mean change -37.76 in the intervention vs. 0.27 in the control group, p < 0.001) were reduced compared to the control group. sRAGE was reduced in both groups. In addition, HbA1c (at two months), total cholesterol, and triglycerides were reduced in the intervention versus the control group. The adoption of healthy cooking methods deserves further research as a possible way of modulating inflammatory markers in patients with CKD.
Malignancies were observed in clinical studies of OLUMIANT [see Adverse Reactions (6.1)]. 

In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lymphomas was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers. In this study, current or past smokers had an additional increased risk of overall malignancies. 

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT, particularly in patients with a known malignancy (other than successfully treated NMSC), patients who develop a malignancy, and patients who are current or past smokers. 

Non-melanoma skin cancers

Non-melanoma skin cancers (NMSCs) have been reported in patients treated with OLUMIANT. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.
The invention aims to provide an injection egg white pig fattening agent and a preparation method thereof, belonging to the technical field of pig raising methods and relating to a drug which is beneficial to development and rapid fattening of a pig. The preparation method mainly comprises the following steps of: carrying out dilution preparation on ten mineral substances like egg white, copper, ferrum, zinc, manganese, calcium, phosphorus, sodium, magnesium, selenium and the like by using distilled water and a glucose solution to form a prepared solution and preparing an injection (10ml per one) by using the prepared solution. The injection fattening is carried out on healthy pigs of 40-50kg. The injection site of the pig is 1-5cm site at the turning of mandible permanent tooth germ abutted with the bone margin site, and a needle head faces the direction of the head and forms an angle of 35-60 degrees with the neck. The invention has the advantages of not having toxic and side effects and taking the complementation and promotion action on development fattening and feed nutrition of the pig. After the pig fattening agent is injected at a time, the appetite of the pig is obviously enhanced and the growing speed is high. The pig fattening agent also takes the obvious effect on enhancing the immunological effect. The invention has the mechanism that through injecting the pig fattening agent to the site approaching the pituitary and the hypothalamus of the pig, the endocrine functions of the pituitary and the hypothalamus of the pig are promoted, and then the pig fatting is emphasized.
The invention discloses attapulgite/green tea toothpaste and a production method thereof. The technical proposal is that: the production method comprises the following steps: steaming for enzyme deactivation, preparing ingredients, low-speed stirring, pulverization and pulping, milling, high-speed stirring, vacuum degassing and packaging. Through the steps, finished products of attapulgite/green tea toothpaste are obtained. The attapulgite/green tea toothpaste contains pasty attapulgite clay, fresh green tea, sodium dodecylsulfate, potassium sorbate, borneol and deionized water. The attapulgite/green tea toothpaste contains attapulgite clay as a major ingredient, has no additives, such as abrasives, adhesives and humectant, and has high quality and low production cost. The attapulgite/green tea toothpaste has soft and fine texture and oral cleaning and refreshing functions, and can adsorb and eliminate odors in oral cavity. The inventive method is suitable for the production of attapulgite/green tea toothpaste, herbal toothpaste and other medicinal toothpaste.
<P>PROBLEM TO BE SOLVED: To provide a modified medicine delivery device which is made easily compatible with a desired designed structure along with an efficient and easier production and moreover, achieves the extremely lower production costs.  <P>SOLUTION: The medicine delivery device comprises the body which has the base end part, the distal end part and an opening at the distal end part. An orifice mechanism at the distal end part of the body communicates with the opening. The orifice mechanism comprises an inner member having the base end part and the distal end part and a coil wound spirally on the circumference of the inner member and the coil and the inner member defines the first passage for transferring the medicine. An inlet is positioned at the base end part of the coil and an outlet at the distal end part of the inner member.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
A system for compliant interaction between parties may include a computing device hosting a compliance and insight platform executing on the computing device. The platform may include a secure room hosted on the platform. The secure room may include a restricted environment that hosts interaction data between users based on one or more interactions rules of the secure room. The secure room may be configured to receive interaction data from a first user in the secure room, provide at least a portion of the interaction data to a second user in the secure room, and blind and restrict the first user and the second user from each other's identity. The platform may further include a moderator of the secure room. The moderator may be configured to moderate the interaction data in the first secure room.
Most Mononegavirales viruses have a GDNQ motif within the L protein, whereas Novirhabdovirus species feature a GDNV motif. This study examined the function of the GDNV motif within the L protein of viral hemorrhagic septicemia virus (VHSV) by modifying its amino acid composition. Substituting the aspartic acid (D) with valine (V) completely abolished polymerase activity in a minigenome assay. Replacing GDNV with GDNQ showed no significant difference in luciferase activity. Further characterization using reverse genetically engineered recombinant viruses revealed that rVHSV-LGDNQ exhibited an accelerated replication rate and higher virus titer in EPC cells than rVHSV-wild. Olive flounder infected with rVHSV-LGDNQ experienced higher early-stage mortality but lower overall mortality than those infected with rVHSV-wild. These findings suggest that while the GDNQ motif may positively influence VHSV replication speed, it may not confer an overall advantage for the ultimate viral pathogenicity.
BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m\^2 together with leucovorin 400 mg/m\^2 will be administered intravenously 5-FU 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.